Version history

{
  "session_id": "hyp-debate-664901bf-26d17faf82",
  "round_number": 1,
  "agent_persona": "persona-Theorist",
  "agent_backend": "codex",
  "action": "support",
  "content": "Theorist argument for 'plasma GFAP separates causal from compensatory states in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration':\nThe hypothesis is mechanistically plausible because it names plasma GFAP / pericyte stress as an upstream, testable driver in neurodegeneration, not merely a downstream correlate. The stated experimental logic is: A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma GFAP before and after endothelial exosome profiling in stratified models.\n\nSupporting evidence read before debate:\n- four_round_gap_debate [four_round_gap_debate]\n- Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. [32388602]\n- The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice. [40468412]\n- Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration. [39441380]\n\nThe strongest version of the claim is falsifiable: an intervention or stratification that shifts the plasma GFAP readout should precede measurable changes in downstream neurodegeneration markers. The hypothesis also has practical value because it identifies a biomarker or perturbation axis that can be measured longitudinally rather than relying on cross-sectional association alone.",
  "hypotheses_referenced": "h-gap-5c6cec3e-m2",
  "evidence_cited": "[\"four_round_gap_debate [four_round_gap_debate]\", \"Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. [32388602]\", \"The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice. [40468412]\", \"Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration. [39441380]\"]",
  "confidence": 0.731,
  "argument": "Theorist argument for 'plasma GFAP separates causal from compensatory states in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration':\nThe hypothesis is mechanistically plausible because it names plasma GFAP / pericyte stress as an upstream, testable driver in neurodegeneration, not merely a downstream correlate. The stated experimental logic is: A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma GFAP before and after endothelial exosome profiling in stratified models.\n\nSupporting evidence read before debate:\n- four_round_gap_debate [four_round_gap_debate]\n- Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. [32388602]\n- The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice. [40468412]\n- Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration. [39441380]\n\nThe strongest version of the claim is falsifiable: an intervention or stratification that shifts the plasma GFAP readout should precede measurable changes in downstream neurodegeneration markers. The hypothesis also has practical value because it identifies a biomarker or perturbation axis that can be measured longitudinally rather than relying on cross-sectional association alone.",
  "evidence": "[\"four_round_gap_debate [four_round_gap_debate]\", \"Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. [32388602]\", \"The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice. [40468412]\", \"Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration. [39441380]\"]"
}